Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.

SystImmune Inc. (SystImmune) today announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has ...

Millions of Americans and Canadians are breathing bad air right now due to wildfire smoke. Here’s what you need to know masks ...

Good day, everyone, and welcome to today's conference call to discuss the 12-month results from our ongoing open-label extension study of TPIP in patients with PAH. Before we start, please note that ...

VO2 max measures the maximum amount of oxygen your body can use during exercise. It’s become one of the buzziest fitness metrics on social media, with influencers and wearable devices touting it as a ...

Several cities in the Midwest and Northeast are ranked among the world’s most polluted cities due to traveling smoke from ...

One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX ® -C (immune globulin injection [human], 10% caprylate ...

The opening ceremony centred on the importance of movement for people living with rheumatic and musculoskeletal diseases (RMD ...

Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being ...

Study examines Qalsody safety after approval “This study is the first to systematically conduct a post-marketing [safety] ...

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple MyelomaPublication Supports Continued ...

Princess Ingrid Alexandra of Norway reportedly borrowed an item from her mum Crown Princess Mette-Marit's archival wardrobe ...